ImmunityBio, Inc.
IBRX
$2.33
-$0.05-2.10%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 38.58% | 31.93% | 29.09% | -28.33% | -26.25% |
| Total Depreciation and Amortization | -9.98% | -8.47% | -5.18% | -6.23% | -5.13% |
| Total Amortization of Deferred Charges | -62.59% | -53.20% | -46.72% | -46.68% | -23.90% |
| Total Other Non-Cash Items | -77.46% | -76.87% | -98.94% | 481.65% | 306.87% |
| Change in Net Operating Assets | -54.98% | -36.17% | -588.36% | -248.38% | -183.38% |
| Cash from Operations | 14.74% | 4.95% | -6.67% | -23.13% | -22.24% |
| Capital Expenditure | 54.50% | 71.18% | 77.48% | 69.36% | 69.87% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 182.42% | 200.18% | -4,800.00% | 29.38% | -678.59% |
| Cash from Investing | 162.54% | 147.75% | 59.81% | 61.58% | -170.51% |
| Total Debt Issued | -75.25% | -77.00% | -78.52% | -6.07% | 67.55% |
| Total Debt Repaid | 67.90% | 45.57% | 16.88% | -12.00% | 15.63% |
| Issuance of Common Stock | 156.23% | 128.68% | 72.29% | -43.13% | -4.59% |
| Repurchase of Common Stock | 64.46% | 59.73% | -58.73% | -196.38% | -1,043.81% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -200.00% | 200.00% | -- | -- | 28,700.59% |
| Cash from Financing | -50.71% | -45.00% | -49.56% | -19.78% | 68.58% |
| Foreign Exchange rate Adjustments | 227.27% | 107.79% | 92.12% | 58.65% | 8.33% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -91.10% | -262.07% | -175.78% | -189.41% | 570.85% |